Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
985 ^USD	+0.45%		+0.28%	+12.15%

May. 23	Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer	MT
May. 23	Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075	CI

Regeneron enters $326 mln pact with US to develop new COVID therapy

August 22, 2023 at 02:30 pm EDT

Aug 22 (Reuters) - Regeneron Pharmaceuticals on Tuesday said it had entered into a contract worth $326 million with a U.S. government agency for the development of next-generation antibody therapy for COVID-19 prevention. (Reporting by Pratik Jain in Bengaluru; Editing by Maju Samuel)

Latest news about Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer	May. 23	MT
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075	May. 23	CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing	May. 22	MT
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate	May. 20	MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115	May. 20	MT
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25	May. 20	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing	May. 17	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $48,636,545, According to a Recent SEC Filing	May. 17	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	May. 17	MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,115 From $1,060	May. 17	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $35,207,110, According to a Recent SEC Filing	May. 16	MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 09:00 AM	May. 14
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group	May. 13	DJ
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review	May. 13	MT
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Dupixent	May. 13	CI
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks	May. 08	CI
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating	May. 07	MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept	May. 03	MT
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126	May. 03	MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177	May. 02	MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016	May. 02	MT
RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189	May. 02	MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...	May. 02
Sector Update: Health Care Stocks Mixed Premarket Thursday	May. 02	MT
Transcript : Regeneron Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02

Chart Regeneron Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Annual Meeting - Abstract No : 2650

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

985 USD

Average target price

1,042 USD

Spread / Average Target

+5.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	116B
BIONTECH SE	-8.14%	23.89B
ARGENX SE	-1.69%	21.58B
GENMAB A/S	-10.60%	18.96B
WUXI APPTEC CO., LTD.	-41.25%	16.96B
BEIGENE, LTD.	-15.33%	16.33B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.14B
SAREPTA THERAPEUTICS, INC.	+28.03%	12.02B
CEREVEL THERAPEUTICS HOLDINGS, INC.	-2.52%	7.58B

Bio Therapeutic Drugs